文献速递免疫规划职业卫生

泰国那黎宣大学医学院医护人员完成两剂CoronaVac后异源第二剂加强针BNT162b2的免疫应答与不良反应

Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
PubMed 文献 · Vaccine · 2023-06-05

本研究在泰国那黎宣大学医学院医护人员中,对完成两剂CoronaVac者接种异源第二剂加强针BNT162b2,检测接种后4周和24周抗SARS-CoV-2刺突蛋白IgG滴度并记录不良反应。接种后4周和24周分别有246/247人(99.6%)IgG阳性,中位滴度分别为299 U/ml和104 U/ml,24周时显著下降;179/247人(72.5%)在接种后3天内出现不良反应,以肌痛、发热、头痛、注射部位疼痛和乏力最常见。

要点

  • 接种异源第二剂加强针BNT162b2后4周和24周,246/247人(99.6%)抗SARS-CoV-2刺突蛋白IgG阳性。
  • 中位特异性IgG滴度在4周为299 U/ml,24周降至104 U/ml,24周时显著下降。
  • 179/247人(72.5%)在接种后3天内出现不良反应,以肌痛、发热、头痛、注射部位疼痛和乏力最常见。

核心结论

  • 完成两剂CoronaVac后接种异源第二剂加强针BNT162b2,可诱导医护人员抗SARS-CoV-2刺突蛋白IgG升高并引起轻微不良反应。

研究设计与样本

  • 研究在泰国那黎宣大学医学院医护人员中开展,受试者完成两剂CoronaVac后接种异源第二剂加强针BNT162b2。
  • 接种后4周和24周检测抗SARS-CoV-2刺突蛋白IgG滴度,并在接种后前3天、4周和24周记录不良反应。
  • 研究注册号为泰国临床试验注册号TCTR20221112001。

主要发现

  • 接种后4周和24周,抗SARS-CoV-2刺突蛋白IgG阳性(>10 U/ml)均为246/247人(99.6%)。
  • 接种后4周中位特异性IgG滴度为299 U/ml(最小值2,最大值29,161),24周为104 U/ml(最小值1,最大值17,920)。
  • 接种后24周中位IgG水平较4周显著下降。
  • 247名参与者中179人(72.5%)在接种后前3天内出现不良反应。
  • 最常见的不良反应为肌痛、发热、头痛、注射部位疼痛和乏力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first COVID-19 vaccination campaign in Thailand began in April 2020, with healthcare workers receiving two doses of inactivated COVID-19 vaccine (CoronaVac). However, the emergence of the delta and omicron variants raised concerns about vaccine effectiveness. The Thai Ministry of Public Health provided the first booster dose (third dose) and second booster dose (fourth dose) of the mRNA vaccine (BNT162b2) for healthcare workers. This study investigated the immunity and adverse reactions elicited by a heterologous second booster dose of BNT162b2 after a two-dose CoronaVac vaccination for COVID-19 in healthcare workers of the Faculty of Medicine, Naresuan University. METHODS: IgG titres against the SARS-CoV-2-spike protein were measured four and 24 weeks after the second booster dose of BNT162b2 in the study participants. Adverse reactions were recorded during the first three days, four weeks and 24 weeks after the second booster dose of BNT162b2. RESULTS: IgG against the SARS-CoV-2-spike protein was positive (>10 U/ml) in 246 of 247 participants (99.6 %) at both four and 24 weeks after the second booster dose of BNT162b2. The median specific IgG titres at four and 24 weeks after the second booster dose of BNT162b2 were 299 U/ml (min: 2, max: 29,161) and 104 U/ml (min: 1, max: 17,920), respectively. The median IgG level declined significantly 24 weeks after the second booster dose of the BNT162b2 vaccine. Of the 247 participants, 179 (72.5 %) experienced adverse reactions in the first three days after the second booster dose of BNT162b2. Myalgia, fever, headache, injection site pain and fatigue were the most common adverse reactions. CONCLUSION: This study demonstrated that a heterologous second booster dose of BNT162b2 after two doses of CoronaVac induced elevated IgG against the SARS-CoV-2-spike protein and caused minor adverse reactions in healthcare workers of the Faculty of Medicine, Naresuan University. This study was registered as Thailand Clinical Trials No. TCTR20221112001.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Makanut S, Wangteeraprasert A, Jitpewngam W, et al. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University. Vaccine. 2023. PMID: 37301707. doi:10.1016/j.vaccine.2023.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。